Tillman Hartley LLC Has $705,000 Stock Holdings in AbbVie Inc. (NYSE:ABBV)

Tillman Hartley LLC cut its stake in shares of AbbVie Inc. (NYSE:ABBV) by 3.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,966 shares of the company’s stock after selling 160 shares during the period. Tillman Hartley LLC’s holdings in AbbVie were worth $705,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of ABBV. Erste Asset Management GmbH raised its position in AbbVie by 7.5% during the fourth quarter. Erste Asset Management GmbH now owns 139,949 shares of the company’s stock valued at $24,911,000 after buying an additional 9,765 shares during the period. Tredje AP fonden raised its position in AbbVie by 2.2% during the fourth quarter. Tredje AP fonden now owns 749,458 shares of the company’s stock valued at $133,179,000 after buying an additional 16,338 shares during the period. Mascoma Wealth Management LLC raised its position in AbbVie by 12.3% during the fourth quarter. Mascoma Wealth Management LLC now owns 797 shares of the company’s stock valued at $142,000 after buying an additional 87 shares during the period. Rakuten Securities Inc. raised its position in AbbVie by 160.6% during the fourth quarter. Rakuten Securities Inc. now owns 357 shares of the company’s stock valued at $63,000 after buying an additional 220 shares during the period. Finally, Jupiter Asset Management Ltd. acquired a new position in AbbVie during the fourth quarter valued at $49,164,000. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Performance

ABBV opened at $211.80 on Thursday. The firm has a market capitalization of $373.91 billion, a P/E ratio of 88.25, a price-to-earnings-growth ratio of 1.62 and a beta of 0.61. The stock’s 50 day moving average price is $189.84 and its two-hundred day moving average price is $187.89. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. AbbVie Inc. has a 12-month low of $153.58 and a 12-month high of $218.66.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same period last year, the business posted $2.79 earnings per share. On average, equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be issued a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date of this dividend is Tuesday, April 15th. AbbVie’s dividend payout ratio (DPR) is currently 273.33%.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Timothy J. Richmond sold 29,917 shares of the firm’s stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $202.90, for a total value of $6,070,159.30. Following the completion of the sale, the executive vice president now owns 44,284 shares in the company, valued at approximately $8,985,223.60. This trade represents a 40.32 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Kevin K. Buckbee sold 18,944 shares of the firm’s stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $203.41, for a total value of $3,853,399.04. Following the completion of the sale, the senior vice president now owns 11,496 shares of the company’s stock, valued at $2,338,401.36. This represents a 62.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 56,439 shares of company stock valued at $11,377,057 in the last 90 days. 0.25% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ABBV. Piper Sandler upped their price target on AbbVie from $212.00 to $220.00 and gave the company an “overweight” rating in a research report on Tuesday, December 17th. Truist Financial upped their price target on AbbVie from $211.00 to $217.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Wells Fargo & Company upped their price target on AbbVie from $210.00 to $240.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Leerink Partners upgraded AbbVie from a “market perform” rating to an “outperform” rating and set a $206.00 target price on the stock in a research note on Friday, November 22nd. Finally, Piper Sandler Companies restated an “overweight” rating and issued a $220.00 target price on shares of AbbVie in a research note on Tuesday, December 17th. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $211.45.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.